Skip to main content
Premium Trial:

Request an Annual Quote

Helicos Inks $20M Credit Facility with GE Healthcare

NEW YORK (GenomeWeb News) – Helicos Biosciences will use a $20 million senior secured credit facility from GE Healthcare Financial Services to shore up its working capital and to fund commercialization efforts, the company said today.
 
The company received an initial $10 million under the facility on Dec. 31, and it will be able to draw down the remaining $10 million through the end of June. The first $10 million will be amortized over 36 months, and Helicos will owe interest-only payments over the initial 12 months.
 
Helicos, which went public in May 2007, said in its November earnings report that it was surviving on minimal revenue from grants while it amped up its R&D spending and took a $10 million net loss for the third quarter.
 
Helicos CEO Steve Lombardi said in a statement that the loan will allow the company to “scale up our manufacturing and build inventory to meet customer demand in 2008 and beyond.”
 
The firm expects to soon launch its HeliScope next-generation sequencing instrument.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.